Novo Nordisk AS (OCSE:NOVO B) Q3 2025: Everything You Need To Know Ahead Of Earnings

This article first appeared on GuruFocus.

Novo Nordisk AS (OCSE:NOVO B) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $77.50 billion, and the earnings are expected to come in at $5.25 per share. The full-year 2025's revenue is expected to be $313.99 billion and the earnings are expected to be $23.83 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 1 Warning Sign with OCSE:NOVO B.

Is OCSE:NOVO B fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Novo Nordisk AS (OCSE:NOVO B) have declined from $314.48 billion to $313.99 billion for the full year 2025 and from $353.78 billion to $331.71 billion for 2026 over the past 90 days. Earnings estimates have decreased from $25.41 per share to $23.83 per share for the full year 2025 and from $28.46 per share to $25.83 per share for 2026 over the past 90 days.

In the previous quarter ending on 2025-06-30, Novo Nordisk AS's (OCSE:NOVO B) actual revenue was $76.86 billion, which beat analysts' revenue expectations of $76.55 billion by 0.40%. Novo Nordisk AS's (OCSE:NOVO B) actual earnings were $5.96 per share, which beat analysts' earnings expectations of $5.94 per share by 0.35%. After releasing the results, Novo Nordisk AS (OCSE:NOVO B) was down by 5.36% in one day.

Based on the one-year price targets offered by 24 analysts, the average target price for Novo Nordisk AS (OCSE:NOVO B) is $439.74 with a high estimate of $720.00 and a low estimate of $232.00. The average target implies an upside of 39.47% from the current price of $315.30.

Based on GuruFocus estimates, the estimated GF Value for Novo Nordisk AS (OCSE:NOVO B) in one year is $979.45, suggesting an upside of 210.64% from the current price of $315.30.

Based on the consensus recommendation from 27 brokerage firms, Novo Nordisk AS's (OCSE:NOVO B) average brokerage recommendation is currently 2.4, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Scroll to Top